| Literature DB >> 28611049 |
Johanna Kondelin1,2, Alexandra E Gylfe1,2, Sofie Lundgren1,2, Tomas Tanskanen1,2, Jiri Hamberg1,2, Mervi Aavikko1,2, Kimmo Palin1,2, Heikki Ristolainen1,2, Riku Katainen1,2, Eevi Kaasinen1,2, Minna Taipale3,4, Jussi Taipale1,2,3,4, Laura Renkonen-Sinisalo5, Heikki Järvinen5, Jan Böhm6, Jukka-Pekka Mecklin7, Pia Vahteristo1,2, Sari Tuupanen1,2, Lauri A Aaltonen1,2,3, Esa Pitkänen8,2.
Abstract
Approximately 15% of colorectal cancers exhibit microsatellite instability (MSI), which leads to accumulation of large numbers of small insertions and deletions (indels). Genes that provide growth advantage to cells via loss-of-function mutations in microsatellites are called MSI target genes. Several criteria to define these genes have been suggested, one of them being simple mutation frequency. Microsatellite mutation rate, however, depends on the length and nucleotide context of the microsatellite. Therefore, assessing the general impact of mismatch repair deficiency on the likelihood of mutation events is paramount when following this approach. To identify MSI target genes, we developed a statistical model for the somatic background indel mutation rate of microsatellites to assess mutation significance. Exome sequencing data of 24 MSI colorectal cancers revealed indels at 54 million mononucleotide microsatellites of three or more nucleotides in length. The top 105 microsatellites from 71 genes were further analyzed in 93 additional MSI colorectal cancers. Mutation significance and estimated clonality of mutations determined the most likely MSI target genes to be the aminoadipate-semialdehyde dehydrogenase AASDH and the solute transporter SLC9A8 Our findings offer a systematic profiling of the somatic background mutation rate in protein-coding mononucleotide microsatellites, allowing a full cataloging of the true targets of MSI in colorectal cancer. Cancer Res; 77(15); 4078-88. ©2017 AACR. ©2017 American Association for Cancer Research.Entities:
Mesh:
Year: 2017 PMID: 28611049 DOI: 10.1158/0008-5472.CAN-17-0682
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701